Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

about

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

Item

http://www.wikidata.org/entity/Q47630577

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Realgar nanoparticles versus A ...... vity against multiple myeloma.

@en

Realgar nanoparticles versus A ...... vity against multiple myeloma.

@nl

type

Item

label

Realgar nanoparticles versus A ...... vity against multiple myeloma.

@en

Realgar nanoparticles versus A ...... vity against multiple myeloma.

@nl

prefLabel

Realgar nanoparticles versus A ...... vity against multiple myeloma.

@en

Realgar nanoparticles versus A ...... vity against multiple myeloma.

@nl

P1476

Realgar nanoparticles versus A ...... ivity against multiple myeloma

@en

P2093

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

Danka Cholujova

http://www.w3.org/2001/XMLSchema#string

David M Dorfman

http://www.w3.org/2001/XMLSchema#string

Peter Balaz

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

Zdenka Bujnakova

http://www.w3.org/2001/XMLSchema#string

P2860

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia

Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia

Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis

Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.

P304

756-771

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14974

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29048129

http://www.w3.org/2001/XMLSchema#string

P932

5705577

http://www.w3.org/2001/XMLSchema#string